Bullish
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer maintenance
Pfizer's TUKYSA® (tucatinib) regimen, in combination with trastuzumab and pertuzumab, has been approved by the U.S. Food and Drug Administration (FDA) as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. This approval offers a new chemotherapy-free maintenance option that may help further delay disease progression.
Key points
- FDA approval of TUKYSA regimen for front-line HER2+ breast cancer maintenance.
- Pfizer declares $0.43 fourth-quarter 2026 dividend, payable December 7, 2026.
- Scotiabank raises Pfizer's price target to $33 from $30, maintains Outperform rating.
Sources
- Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness Wire · October 7, 2026
- Pfizer Declares Fourth-Quarter 2026 DividendBusiness Wire · October 6, 2026
- Pfizer price target raised to $33 from $30 at ScotiabankTheFly · October 6, 2026
AI-generated from public news sources. Not financial advice.
